Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Consortium for Childhood Cancer Predisposition. For a description of this project, see the consortium grant made to the lead institution: Emory University, Atlanta, GA.

The North American Consortium for Histiocytosis, or NACHO, is a consortium dedicated to clinical and translational studies and biological research for histiocytic disorders. Histiocytic disorders are a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation. This group is made up of a wide variety of conditions that can affect both children and adults. NACHO is operated through a partnership between St. Jude Children's Research Hospital and Texas Children's Hospital. NACHO was created in 2014 in order to meet the need for a coordinated effort to combat histiocytic disorders. Histiocytic disorders have not previously been a priority for large, multi-site research cooperative groups, which has left these disorders with a lack of progress towards increased knowledge and new therapies. NACHO aims to bring together various hospitals and research institutions to collaborate and share experiences in order to further the advancement of histiocytic disorders. NACHO currently has 49 member institutions across the United States and Canada and aims to keep expanding so that children all over North America will have access to clinical trials that could save their lives. Funds administered by St. Jude Children's Research Hospital.

Move for Miles Childhood Cancer Foundation is generously supporting this research because they know research is how to drive change and improve the future. The foundation's inspiration comes from Miles himself who was diagnosed with Langerhans Cell Histiocytosis. Even through his fight, he has a joy and love for life and being outdoors. His family calls him sMiles because even though he has faced many obstacles, he still keeps smiling and moving.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

Childhood cancer remains the leading cause of illness-related death in children. We now know that inherited genetic abnormalities contribute to cause cancer in many more children than previously understood. Children with Cancer Predisposition Syndromes (CPS) have a high risk of cancer, and we have a unique opportunity to prevent or detect cancer at early stages to improve their survival, as well as to better understand mechanisms of cancer development for all pediatric tumors. However, these CPS are rare and difficult to study in individual institutions. Thus, the creation of the Consortium for Childhood Cancer Predisposition, through which we will study surveillance and prevention strategies efficiently, by utilizing coordinated efforts to collect data and samples from patients with a CPS (creating a registry and biorepository). The Consortium will initially be composed of seven institutions and led by individuals who have already worked together to have significant impacts in this field, and will engage syndrome-specific advocacy groups to accelerate patient-centered advances. We expect that the impact of this Consortium will be improved outcomes for those at the highest risk of cancer through better identification, early tumor detection, optimized psychosocial support and cancer prevention. Funds administered by Emory University.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Consortium for Childhood Cancer Predisposition. For a description of this project, see the consortium grant made to the lead institution: Emory University, Atlanta, GA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Consortium for Childhood Cancer Predisposition. For a description of this project, see the consortium grant made to the lead institution: Emory University, Atlanta, GA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

Retinoblastoma, a highly curable cancer of the eye, is associated with many long term difficulties due to the effects of therapy. Carboplatin is an important drug for this disease but its effects on hearing loss have not been studied in depth. Certainly, children already compromised in vision will be substantially impacted if in fact they acquire hearing impairment. Recently, a consortium of thirteen retinoblastoma treatment centers have been assembled to study the health problems of hundreds of patients with this condition. This consortium investigates the long term toxicity experienced by these patients from their cancer condition, and also examines how the long term side effects impact both the intellectual function of these children, and their quality of life. Dr. Hayashi is working to clearly define the nature and scope of hearing loss in this patient population and the impact of this hearing loss on the overall well-being of the child. With this information, he hopes to advance efforts to minimize the long term hearing loss of these children, but also to provide interventions in the future to optimize the health and well-being of those patients already impacted by their therapy.

Adolescent and young adult (AYA) cancer patients face depression and anxiety that are unique to their cancer diagnoses. Existing psychotherapies that work well for general depression and anxiety do not work effectively for the AYA population. Untreated psychological stress and distress (like depression or anxiety) will result in young patients' non-compliance to medical treatment, low quality of life among others. These psychological challenges stand in the way between these patients and a successful recovery. Therefore, as the recipient of the Julia's Legacy of Hope St. Baldrick’s Supportive Care Research Grant, Dr. Zhang is developing and evaluating a computer-based cognitive behavioral therapy that is specifically tailored for AYA cancer patients. Results of this study will improve the treatment for AYA cancer patients' depression and anxiety to improve their medical compliance and quality of life.

This grant is funded by and named for Julia's Legacy of Hope, a Hero Fund that honors her positive, courageous spirit and carries out her last wish: "no child should have to go through what I have experienced". Diagnosed at 16 with Ewing sarcoma, Julia fought cancer and survived only to be stricken by a secondary cancer as a result of treatment. Her family hopes to raise awareness and funds for research especially for Adolescent and Young Adult (AYA) patients.